Scleroderma Induced by Pembrolizumab: A Case Series.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28599746.
- Also identified by DOI 10.1016/j.mayocp.2017.03.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Melanoma
- Scleroderma, Diffuse
- Scleroderma, Limited